NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 189-196

  Orucevic, A ^a   Lala, P K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Capillary leak syndrome; Interleukin 2 cancer immunotherapy; Mammary adenocarcinoma; NG nitro L arginine methyl ester; Nitric oxide

Indexed keywords

AMINO ACID; ARGININE METHYL ESTER; CYTOKINE; INTERLEUKIN 2; NITRATE; NITRIC OXIDE; NITRITE; ANTINEOPLASTIC AGENT; ARGININE; DRUG DERIVATIVE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CAPILLARY PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LUNG; LUNG EDEMA; LUNG METASTASIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLEURA CAVITY; PRIORITY JOURNAL; SPLEEN; TUMOR VOLUME; WATER CONTENT; WATER RETENTION; ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; C3H MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; IMMUNOTHERAPY; LUNG TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; PATHOLOGY; PLEURA EFFUSION;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; CAPILLARY PERMEABILITY; COMBINED MODALITY THERAPY; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-2; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLEURAL EFFUSION, MALIGNANT; PULMONARY EDEMA; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 0029671094     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.34     Document Type: Article

References (52)

1. ALBINA JE, ABATE JA AND HENRY WL JR. (1991). Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFNγ in the induction of nitric oxide-synthesising pathway. J. Immunol., 147, 144-148.
2. AMADOR J-F, VAZQUEZ AM, CABRERA L, BARRAL AM, GENDELMAN R AND JONDAL M. (1991). Toxic effects of interleukin-2-activated lymphocytes on vascular endothelial cells. Nat. Immun. Cell Growth Regul., 10, 207-215.
3. ANDRADE SP, HART IR AND PIPER PJ. (1992). Inhibitors of nitric oxide synthase selectively reduce flow in tumour-associated neovasculature. Br. J. Pharmacol., 107, 1092-1095.
4. ARONSON FR, LIBBY P, BRANDON EP, JANICKA MW AND MIER JW. (1988). IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. J. Immunol., 141, 158-163.
5. BAGULEY BC, CALVELEY SB, CROWE KK, FRAY LM, O'ROURKE SA AND SMITH GP. (1989). Comparison of the effects of flavone acetic acid, fostriecin, homoharringtone and tumour necrosis factor a on colon 38 tumours in mice. Eur. J. Cancer Clin. Oncol., 25, 263-269.
6. BRODT P, PARHAR RS, SANKER P AND LALA PK. (1985). Studies on clonal heterogeneity in two spontaneously metastasising mammary carcinomas of recent origin. Int. J. Cancer, 35, 265-273.
7. BUTTERY LDK, SPRINGALL DR, ANDRADE SP, RIVEROS-MORENO V, HART I, PIPER PJ AND POLAK JM. (1993). Induction of nitric oxide synthase in the neo-vasculature of experimental tumours in mice. J. Pathol., 171, 311-319.
8. DAVISON W AND WOOF C. (1978). Comparison of different forms of cadmium as reducing agents for the batch determination of nitrate. Analyst, 103, 403-406.
9. DUTCHER JP, CREEKMORE S, WEISS GR, MARGOLIN K, MARKOWITZ AB, ROPER M, PARKINSON D, CIOBANU N, FISHER RI, BOLDT DH, DOROSHOW JH, RAYNER AA, HAWKINS M AND ATKINS M. (1989). A phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma. J. Clin. Oncol., 7, 477-485.
10. G-nitroarginine in brain in vitro and in vivo. Biochem. Biophys. Res. Commun., 176, 1136-1141.
11. ETTINGHAUSEN SE, PURI RK AND ROSENBERG SA. (1988). Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst., 80, 177-188.
12. FAGGIONI R, ALLAVENA P, CANTONI L, CARELLI M, DEMITRI MT, DELGADO R, GATTI S, GNOCCHI P, ISETTA AM, PAGANIN C, ECHTENACHER B, ALBINI E AND GHEZZI P. (1994). Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J. Immunother., 15, 194-201.
13. FISHER RI, COLTMAN CA, DOROSHOW JA, RAYNER AA, HAWKINS MJ, MIER JW, WIERNIK P, MCMANNIS JD, WEISS GR, MARGOLIN KA, GEMLO BT, HOTH DF, PARKINSON DR AND PAIETTA E. (1988). A phase II study of interleukin-2 and lymphokine activated killer cells (LAK) in metastatic renal cancer. Ann. Intern. Med., 108, 518-523.
14. G-nitroarginine. Biochemistry, 32, 8512-8517.
15. 15N]nitrate in biological fluids. Anal. Biochem., 126, 131-138.
16. G-methylarginine. Biochem. Biophys. Res. Commun., 170, 96-102.
17. HIBBS JB JR, WESTENFELDER C, TAINTOR R, VAVRIN Z, KABLITZ C, BARANOWSKI RL, WARD JH, MENLOVE RL, MCMURRY MP, KUSHNER JP AND SAMLOWSKI WE. (1992). Evidence for cytokine-inducible nitric oxide synthesis from 1-arginine in patients receiving interluekin-2 therapy. J. Clin. Invest., 89, 867-877.
18. HOFFMAN RA, LANGREHR JM, BILLIAR TR, CURRAN RD AND SIMMONS RL. (1990). Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J. Immunol., 145, 2220-2226.
19. IALENTI A, MONCADA S AND DI ROSA M. (1993). Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol., 110, 701-706.
20. KAHALEH MB, SMITH EA, SOMA Y AND LEROY EC. (1988). Effect of lymphotoxin and tumour necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Clin. Immunol. Immunopath.,49, 261-272.
21. KELM M, FEELISCH M, GRUBE R, MOTZ W AND STAUER BE. (1992). Metabolism of endothelium-derived nitric oxide in human blood. In The Biology of Nitric Oxide. Moncada S, Marletta MA, Hibbs JB, Jr and Higgs EA. (eds) pp.319-322. Portland Press: London.
22. G-nitro-L-arginine methyl ester (L-NAME) administration slows the growth of malignant tumours in rodents (abstract). Endothelium, 1, s52.
23. KENNOVIN GD, HIRST DG, STRATFORD MRL AND FLITNEY FW. (1994). Inducible nitric oxide synthase is expressed in tumour-associated vasculature: inhibition retards tumour growth in vivo. In Biology of Nitric Oxide Vol 4. Enzymology, Biochemistry and Immunology, Moncada S, Feelisch M, Busse R and Higgs EA (eds) pp.473-479. Portland Press: London.
24. LALA PK AND PARHAR RS. (1993). Eradication of sponaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int. J. Cancer, 54, 677-684.
25. LALA PK, PARHAR RS AND SINGH P. (1986). Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumour-bearing mice and prevents tumour metastasis. Cell. Immunol., 99, 108-118.
26. LANCASTER JR JR AND HIBBS JB JR. (1990). EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proc. Natl Acad. Sci. USA, 87, 1223-1227.
27. LEJEUNE P, LAGADEC P, ONIER N, PINARD D, OHSHIMA H AND JEANNIN J-F. (1994). Nitric oxide involvement in tumour-induced immunosuppression. J. Immunol., 152, 5077-5083.
28. MARGOLIN KA, RAYNER AA, HAWKINS MJ, ATKINS MB, DUTCHER JP, FISHER RI, WEISS GR, DOROSHOW JH, JAFFE HS, ROPER M, PARKINSON DR, WIERNIK PH, CREEKMORE SP AND BOLDT DH. (1989). Interleukin-2 and lymphokine-activated killer cell therapy of solid tumours: analysis of toxicity and management guidelines. J. Clin. Oncol., 7, 486-498.
29. MERTENS WC, BRAMWELL VHC, BANERJEE D, GWADRY-SRIDHAR F, AL-MUTTER N, PARHAR RS AND LALA PK. (1993). Chronic oral indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced renal cell carcinoma. Cancer Biotherapy, 8, 229-233.
30. MILLS CD, SHEARER J, EVANS R AND CALDWELL MD. (1992). Macrophage arginine metabolism and inhibition or stimulation of cancer. J. Immunol., 149, 2709-2714.
31. MONCADA S AND HIGGS A. (1993). The L-arginine nitric oxide pathway. N. Engl. J. Med., 329, 2002-2012.
32. MONTESANO R, ORCI L AND VASSALLI P. (1985). Human endothelial cell cultures: Phenotypic modulation by leukocyte interleukins. J. Cell. Physiol., 122, 424-434.
33. NUSSLER AK AND BILLIAR TR. (1993). Inflammation, immunoregulation, and inducible nitric oxide synthase. J. Leuk. Biol., 54, 171-178.
34. OCHOA JB, CURTI B, PEITZMAN AB, SIMMONS RL, BILLIAR TR, HOFFMAN R, RAULT R, LONGO DL, URBA WJ AND OCHOA AC. (1992). Increased circulating nitrogen oxides after human tumour immunotherapy: correlation with toxic hemodynamic changes. J. Natl Cancer Inst., 84, 864-867.
35. G-methyl-L-arginine and indomethacin on IL-2 induced pulmonary oedema and pleural effusion (abstract). Proc Am. Assoc. Cancer Res., 33, 332.
36. G-methyl-L-arginine and indomethacin on IL-2 induced capillary leakage in tumour-bearing mice (abstract). Proc. Am. Assoc. Cancer Res., 34, 459.
37. G-nitro-L-arginine, a nitric oxide inhibitor, on IL-2 induced capillary leak syndrome (abstract). Proc. Canad. Fed. Biol. Soc., 37th annual meeting, 117.
38. G-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interlukin-2-induced capillary leak syndrome in healthy mice. J. Immunother., in press.
39. G-methyl-L-Arginine, an inhibitor of nitric oxide synthesis, on IL-2 induced capillary leakage and anti-tumor responses in healthy and tumor bearing mice. (submitted).
40. PARKINSON DR, FISHFR RI, RAYNER AA, PAIETTA E, MARGOLIN KA, WEISS GR, MIER JW, SZNOL M, GAYNOR ER, BAR MH, GUCALP R, BOLDT DH, MILLS B AND HAWKINS MJ. (1990). Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J. Clin. Oncol., 8, 1630-1636.
41. PURI RK, TRAVIS WD AND ROSENBERG SA. (1989). Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1α in vivo. Cancer Res., 49, 969-976.
42. ROSENBERG SA. (1989). Clinical immunotherapy studies in the surgery branch of the US National Cancer Institute. Cancer Treat. Rev., 16 (Suppl A), 115-121.
43. ROSENBERG SA, MULE JJ, SPIESS PJ, REICHART CM AND SCHWARZ SL. (1985). Regression of established pulmonary metastasis and subcutaneous tumour mediated by systemic administration of high dose recombinant interleukin 2. J. Exp. Med., 161, 1169-1188.
44. ROSENBERG SA, LOTZE MT, MUUL LM, CHANG AE, AVIS FP, LEITMAN S, LINEHAM M, ROBERTSON CN, LEE RE, RUBIN JT, SEIPP CA, SIMPSON C AND WHITE DE. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316, 889-897.
45. ROSENSTEIN M, ETTINGHAUSEN SE AND ROSENBERG SA. (1986). Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol., 137, 1735-1742.
46. SAARLOOS MN, KHOO NKS AND LALA PK. (1992). Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells. Cancer Res., 52, 6452-6462.
47. SIEGEL JP AND PURI PK. (1991). Interleukin-2 toxicity. J. Clin. Oncol., 9, 694-704.
48. STUEHR DJ AND MARLETTA MA. (1985). Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl Acad. Sci. USA, 82, 7738-7742.
49. THOMSEN LL, LAWTON FG, KNOWLES RG, BEESLEY JE, RIVEROS-MORENO V AND MONCADA S (1994). Nitric oxide synthase activity in human gynecological cancer. Cancer Res., 54, 1352-1354.
50. WELBOURN R, GOLDMAN G, KOBZIK L, VALERI CR, HECHTMAN HB AND SHEPRO D. (1991). Attenuation of IL-2-induced multisystem organ oedema by phalloidine and antamanide. J. Appl. Physiol., 70, 1364-1368.
51. WOOD PJ, STRATFORD IJ, ADAMS GE, SZABO C, THIEMERMANN C AND VANE JR. (1993). Modification of energy metabolism and radiation response of murine tumour by changes in nitric oxide availability. Biochem. Biophys. Res. Commun., 192, 505-510.
52. ZAR JH. (1974). Biostatistical Analysis. Prentice-Hall: Englewood Cliffs, NJ.